retatrutide fda approval status november 2025 Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Is Retatrutide FDA Approved? Current

GLP-1 medications typically begin lowering blood glucose within 1-2 weeks of starting treatment, though optimal glycemic control usually requires 12-16 weeks as the dose is gradually increased

Obstructions can cause severe abdominal pain, vomiting, bloating, and the inability to pass gas or have a bowel movement

Moderate Reactions Characteristics: Moderate reactions might involve more noticeable rashes, persistent itching, and discomfort

For reference on what standard titration looks like, the starting dose of tirzepatide guide covers what patients typically experience in the early weeks

There is no wrong choice between these medications for most candidates